1.63
+0.03(+1.88%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.61 |
| Day High | 1.63 |
| Day Low | 1.56 |
| 52-Week High | 8.77 |
| 52-Week Low | 0.99 |
| Volume | 930,473 |
| Average Volume | 2.05M |
| Market Cap | 146.61M |
| PE | -0.64 |
| EPS | -2.54 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 2.51 |
| Change | 0.03 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $163 as of July 04, 2025 at a share price of $1.63. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $143.61 as of July 04, 2025 at a share price of $1.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio Announces Pricing of Public Offering of Securities
GlobeNewswire Inc.
Jun 11, 2025 1:54 PM GMT
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specif
Cabaletta Bio Announces Proposed Public Offering of Securities
GlobeNewswire Inc.
Jun 11, 2025 10:15 AM GMT
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specif
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
GlobeNewswire Inc.
Jun 11, 2025 10:00 AM GMT
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – Al